Byline: John Russell
Oct. 2--Drug maker Eli Lilly and Co. is teaming with General Electric to try to predict how cancer drugs will work in certain patients.
The goal is to develop a set of research tools to help show how cancers respond to targeted therapies as part of a growing movement known as personalized medicine.
Indianapolis-based Lilly signed a three-year research agreement with GE's Global Research unit, the two companies said Monday.
They will collaborate to find key protein and gene signatures that will predict the likelihood that a medication will be effective in treating certain cancers. The signatures then can be used to select patients who are ...